Please login to the form below

Not currently logged in
Email:
Password:

Moventig

This page shows the latest Moventig news and features for those working in and with pharma, biotech and healthcare.

Grünenthal buys Zomig rights as AZ slimming drive continues

Grünenthal buys Zomig rights as AZ slimming drive continues

This work has seen it agree deals with TerSera Therapeutics ($320m for Zoladex), ProStakan ($70m for Moventig), Aspen ($770m for seven anaesthetics drugs) and, most recently, Recordati ($300m for two blood

Latest news

  • FDA approves Synergy's constipation drug Trulance FDA approves Synergy's constipation drug Trulance

    The latter indication is also targeted by AstraZeneca's Movantik (naloxegol), recently sold to ProStrakan in Europe where it is marketed as Moventig.

  • AstraZeneca sells rights to seven anaesthetics in $770m deal AstraZeneca sells rights to seven anaesthetics in $770m deal

    Valeant. ProStraken obtained the European rights to AZ's opioid-induced constipation treatment Moventig (naloxegol), and the firm sold Entocort (budesonide), its inflammatory bowel disease therapy, to Tillotts Pharma.

  • AZ sells Zurampic rights to Gruenenthal for $230m AZ sells Zurampic rights to Gruenenthal for $230m

    In recent months the company has sold late-stage psoriasis candidate brodalumab to Valeant, transferred European rights to its opioid-induced constipation treatment Moventig (naloxegol) to ProStrakan and divested ex-US

  • AZ adds gout drug Zurampic to asset sale AZ adds gout drug Zurampic to asset sale

    Last month, AZ sold European rights to its opioid-induced constipation treatment Moventig (naloxegol) to ProStrakan and transferred Chinese rights to two elderly cardiovascular drugs - Plendil (felodipine) and Imdur (isosorbide mononitrate) -

  • AZ offloads more products in slimming drive AZ offloads more products in slimming drive

    AZ offloads more products in slimming drive. Will invest Moventig, Plendil and Imdur proceeds in its R&D pipeline. ... Moventig was approved in Europe in 2014 and brought in revenues of just $29m for AZ last year.

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    $110. AstraZeneca/ Kyowa Hakko Kirin. Opioid-induced constipation – Moventig. Licence. $70.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics